{"success":true,"data":{"pressRelease":{"id":"164185","rtpr_id":"nGNX2vn28W-20261008","ticker":"MDCX","exchange":"NASDAQ","all_tickers":["MDCX"],"title":"Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value","author":"Globe Newswire","published_at":"2026-10-08T12:00:01.032Z","article_body":"PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:\nMDCX) (“Medicus” or the “Company”), a precision guided, biotech/life\nsciences company focused on advancing novel and potentially disruptive\ntherapeutic assets, today provided a shareholder update celebrating its third\nanniversary, highlighting three years of progress, focused on execution and\ncapital efficient drug development. The Company has advanced its\ntransformation into a precision oncology-led biotechnology company, with a\nportfolio of select novel assets, anchored by CD228V, an investigational\nantibody-drug conjugate molecule utilizing Pfizer’s established vedotin\nlinker-payload platform, SkinJect for basal cell carcinomas in patients with\nGorlin syndrome and Teverelix for development opportunities in urology and\nwomen’s health.\n\nThis transformation, outlined in our recent strategic update, reflects\nprogress in clinical advancement, strategic acquisitions, and investment in\nthe people and capabilities needed to execute. From a company centered on\nSkinJect, we have built a portfolio with multiple potential paths to clinical\nand commercial value.\n\nOur progress has occurred alongside stock-price volatility and pullback. We\nmust make a concerted effort to explain more clearly, when we can, how the\ninvestments made to date position Medicus and support that explanation with\nmeasurable results.\n\nBuilding the Foundation for Potential Long-Term Value\n\nOur strategy is to identify promising therapeutic assets with existing\nscientific and clinical foundations and concentrate incremental investment on\nmilestones that can strengthen their development prospects and partnering\nvalue.\n\nOver these three years, we have assembled a board and management team and\nestablished the clinical, regulatory, financial, and governance capabilities\nneeded to advance our programs. Commencing in October 2023, our progression\nfrom the TSX Venture Exchange to Nasdaq in November 2024, broadened our access\nto public capital markets. Approximately $90 million raised through equity and\ndebt financing supported clinical development, strategic acquisitions, and\norganizational operations, while retaining resources for ongoing requirements.\n\nThat investment has given Medicus a broader portfolio and the capacity to\npursue more complex development opportunities. Its ultimate return will depend\non the clinical evidence we generate, the partnerships we secure, and the\ndiscipline with which we manage future spending.\n\nCD228V and the Opportunity in Targeted Cancer Therapy\n\nAntibody-drug conjugates, or ADCs, combine an antibody that recognizes a\ntarget on cancer cells with a potent cancer-killing payload. Their promise\nlies in directing treatment toward tumor cells, although the balance between\nantitumor activity and toxicity depends on the target, molecular design, and\nclinical setting.\n\nCD228V brings together a less crowded solid-tumor target, second-generation\nmolecular engineering, and an existing clinical and manufacturing foundation.\nIt targets melanotransferrin, also known as CD228, a cell-surface protein\nassociated with melanoma and expressed across several other solid tumors. Its\nexpression and potential for internalization make it an attractive target for\ndelivering an ADC payload.\n\nOur initial priority is melanoma, particularly relapsed, refractory, or\nimmunotherapy-resistant disease, where additional treatment options are\nneeded. We intend to integrate biomarker work into development to better\nunderstand which patients may benefit.\n\nWe believe CD228V also has potential beyond melanoma, including in\nCD228-expressing lung, head and neck, and esophageal cancers. CD228V is early\nin development, and neither its efficacy nor an improved safety profile has\nbeen established; no approved therapy has yet validated CD228 as a treatment\ntarget.\n\nWe believe the combination of target biology, molecular design, and\ndevelopment readiness gives CD228V a compelling place in our portfolio. Our\ngoal is to translate that foundation into evidence that can support further\ndevelopment and attract partners with complementary capabilities.\n\nSkinJect and a Focused Gorlin Syndrome Strategy\n\nWe completed the SKNJCT-003 Phase 2 study, evaluated its findings, and\nidentified the 200-microgram dose for further development. The FDA\nsubsequently authorized initiation of SKNJCT-005, our planned registrational\nstudy in patients with Gorlin syndrome, an autosomal dominant rare disease.\n\nPatients with Gorlin syndrome face a lifetime burden of recurrent basal cell\ncarcinomas and repeated procedures. We believe this population provides a\nfocused setting in which to evaluate SkinJect as a localized treatment option.\n\nThe completed work has informed dose selection and defined the next study,\nproviding a clearer basis for allocating resources and evaluating potential\npartnerships. Additional clinical evidence and regulatory review remain\nnecessary.\n\nTeverelix and Partner Ready Development Opportunities\n\nThe acquisition of Antev in August 2025 expanded our portfolio into urology\nand women’s health through Teverelix, an investigational, next generation,\nGnRH antagonist. We subsequently strengthened its underlying economics by\nreducing the royalty rate and refined its priorities to acute urinary\nretention relapse prevention and symptomatic endometriosis, alongside a\npartnership-led strategy in advanced prostate cancer patients with high\ncardiovascular risk profile.\n\nOur recent submission of an optimized registrational protocol for advanced\nprostate cancer is intended to incorporate previously FDA-cleared\ndose-optimization work into a proposed integrated development program. Subject\nto FDA review, this approach is designed to give potential partners a clearer\nplan for advancing the asset.\n\nThe Next Phase of Execution\n\nOur priorities are to advance selected clinical and regulatory milestones,\nalign organizational costs with those priorities, and pursue licensing,\nco-development, and other strategic opportunities. Partnerships could\ncontribute non-dilutive development funding and expertise while reducing the\ncapital Medicus would otherwise need to provide. Their timing, terms, and\ncompletion remain uncertain.\n\nFor our shareholders, we continue to strive to help make the connection\nbetween our portfolio and potential value more tangible. We are committed to\nexplain the significance of each milestone, the resources required to reach\nit, and the decisions it enables. The measure of our progress should be\nstronger clinical evidence, clearer development pathways, and transactions\nthat support continued advancement.\n\nWe remain confident in the purpose of our work and committed to responsible\ncapital allocation. We have built a company with a broader scientific\nopportunity than when we began. Our mission is to demonstrate what that\nopportunity can deliver for patients and shareholders.\n\nFor further information contact:\n\nCarolyn Bonner, President and Chief Financial Officer\n(610) 636-0184\ncbonner@medicuspharma.com\n\nAnna Baran-Djokovic, SVP Investor Relations \n(305) 615-9162\nadjokovic@medicuspharma.com\n\nAbout Medicus Pharma Ltd.\n\nMedicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences\ncompany focused on advancing the clinical development programs of novel and\npotentially disruptive therapeutic assets. The Company is actively engaged in\nmultiple countries across three continents.\n\nThe Company’s current therapeutic assets are:\n\nCD228V ADC, an investigational antibody-drug conjugate molecule utilizing\nPfizer’s established vedotin linker-payload platform, directed against\nmelanotransferrin (CD228), a cell-surface protein expressed across multiple\nsolid tumor types, such as melanoma, squamous non-small cell lung cancer\n(NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.\n\nSkinJect®, an investigational novel localized immuno-oncology precision\nproduct focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome\npatients, a rare autosomal dominant disease also called nevoid BCC syndrome.\n\nTeverelix®, an investigational next-generation GnRH antagonist, is being\ndeveloped as a first-in-market product for cardiovascular high-risk advanced\nprostate cancer patients, patients with acute urinary retention relapse (AURr)\nepisodes due to enlarged prostate and symptomatic endometriosis.\n\nMedicus’ strategy is to advance select programs through Phase 2\nproof-of-concept and key clinical and regulatory inflection points that\nsubstantially reduce development risk and increase their attractiveness to\npotential pharmaceutical partners. By generating decision-grade clinical,\nregulatory and operational datasets, the Company seeks to create opportunities\nfor strategic collaborations, regional licensing transactions and broader\ncommercialization partnerships with established pharmaceutical companies. As\ndata matures across its programs, Medicus intends to continue building\ndifferentiated development packages designed to maximize asset value while\nmaintaining capital efficiency and development focus.\n\nCautionary Notice on Forward-Looking Statements\n\nCertain information in this news release constitutes “forward-looking\nstatements” or “forward-looking information” within the meaning of the\nU.S. Private Securities Litigation Reform Act of 1995 and other applicable\nsecurities laws (collectively, “forward-looking statements”).\n“Forward-looking statements” are defined as disclosure regarding possible\nevents, conditions or financial performance that is based on assumptions about\nfuture economic conditions and courses of action and includes, without\nlimitation, statements regarding the development of SkinJect® and the\npotential benefits thereof for those suffering with Gorlin Syndrome, the\nplanned initiation, timing, design, conduct and results of the SKNJCT-005\nregistrational study in patients with Gorlin Syndrome, the development of\nTeverelix® and expectations concerning, and future outcomes relating to, the\ndevelopment, advancement and commercialization of Teverelix® for AURr,\ncardiovascular high-risk advanced prostate cancer, women’s health\nindications like endometriosis, the FDA’s feedback regarding the Company’s\nPhase 2b/3 registration-intent protocol for Teverelix® in APC, the proposed\ndesign of the Phase 2b/3 registration-intent program, the potential to reduce\nthe overall planned APC clinical development program from approximately 1,500\npatients to approximately 600 patients, the establishment of a defined,\ncapital-efficient and partner-ready registrational pathway for Teverelix®\nwithout Medicus independently funding an additional APC clinical development\nstudy, Medicus’ intent and ability to out-license or otherwise strategically\npartner the Teverelix® APC program, the anticipated completion of GMP-grade\nmanufacturing, quality-release and other clinical study readiness steps before\nthe end of 2026, whether the proposed cardiovascular-focused registrational\nstrategy, including the 12-month non-calcified coronary plaque endpoint\nassessed using non-invasive coronary CCTA and the evaluation of Teverelix®\neffects on APC patients at increased cardiovascular risk, could support\nregistration, the Company’s capital-efficient portfolio strategy and the\nanticipated benefits thereof, the Company’s co-development with Pfizer with\nrespect to CD228V and the anticipated benefits thereof, the Company’s plans\nand expectations relating to the development, manufacture and\ncommercialization of CD228V across human therapeutic indications, including\nthe Company’s intention to focus initial development on melanoma with\npotential subsequent development in squamous non-small cell lung cancer\n(NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer,\nthe timing, design, conduct and results of any future clinical study of\nCD228V, and the potential market opportunities related to CD228V, SkinJect®\nand Teverelix® and the Company’s other therapeutic assets. Forward-looking\nstatements are often, but not always, identified by the use of such terms as\n\"may\", “on track”, “aim”, \"might\", \"will\", \"will likely result\",\n“could,” “designed,” \"would\", \"should\", \"estimate\", \"plan\", \"project\",\n\"forecast\", \"intend\", \"expect\", \"anticipate\", \"believe\", \"seek\", \"continue\",\n\"target\", “goal”, “strive”, “intended”, “potential” or the\nnegative and/or inverse of such terms or other similar expressions. These\nstatements involve known and unknown risks, uncertainties and other factors,\nwhich may cause actual results, performance or achievements to differ\nmaterially from those expressed or implied by such statements, including those\nrisk factors described in the Company's annual report on form 10-K for the\nyear ended December 31, 2025, and in the Company's other public filings on\nEDGAR and SEDAR+, which may impact, among other things, the trading price and\nliquidity of the Company's common shares. Forward-looking statements contained\nin this news release are expressly qualified by this cautionary statement and\nreflect our expectations as of the date hereof and thus are subject to change\nthereafter. The Company disclaims any intention or obligation to update or\nrevise any forward-looking statements, whether as a result of new information,\nfuture events or otherwise, except as required by law. Readers are further\ncautioned not to place undue reliance on forward-looking statements as there\ncan be no assurance that the plans, intentions or expectations upon which they\nare placed will occur. Such information, although considered reasonable by\nmanagement at the time of preparation, may prove to be incorrect and actual\nresults may differ materially from those anticipated.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0f5af1d1-dfba-4810-baac-d1922c0558c1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2vn28W-20261008","title":"Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value","author":"Globe Newswire","ticker":"MDCX","created":"2026-10-08T12:00:01.032Z","tickers":["MDCX"],"exchange":"NASDAQ","article_body":"PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:\nMDCX) (“Medicus” or the “Company”), a precision guided, biotech/life\nsciences company focused on advancing novel and potentially disruptive\ntherapeutic assets, today provided a shareholder update celebrating its third\nanniversary, highlighting three years of progress, focused on execution and\ncapital efficient drug development. The Company has advanced its\ntransformation into a precision oncology-led biotechnology company, with a\nportfolio of select novel assets, anchored by CD228V, an investigational\nantibody-drug conjugate molecule utilizing Pfizer’s established vedotin\nlinker-payload platform, SkinJect for basal cell carcinomas in patients with\nGorlin syndrome and Teverelix for development opportunities in urology and\nwomen’s health.\n\nThis transformation, outlined in our recent strategic update, reflects\nprogress in clinical advancement, strategic acquisitions, and investment in\nthe people and capabilities needed to execute. From a company centered on\nSkinJect, we have built a portfolio with multiple potential paths to clinical\nand commercial value.\n\nOur progress has occurred alongside stock-price volatility and pullback. We\nmust make a concerted effort to explain more clearly, when we can, how the\ninvestments made to date position Medicus and support that explanation with\nmeasurable results.\n\nBuilding the Foundation for Potential Long-Term Value\n\nOur strategy is to identify promising therapeutic assets with existing\nscientific and clinical foundations and concentrate incremental investment on\nmilestones that can strengthen their development prospects and partnering\nvalue.\n\nOver these three years, we have assembled a board and management team and\nestablished the clinical, regulatory, financial, and governance capabilities\nneeded to advance our programs. Commencing in October 2023, our progression\nfrom the TSX Venture Exchange to Nasdaq in November 2024, broadened our access\nto public capital markets. Approximately $90 million raised through equity and\ndebt financing supported clinical development, strategic acquisitions, and\norganizational operations, while retaining resources for ongoing requirements.\n\nThat investment has given Medicus a broader portfolio and the capacity to\npursue more complex development opportunities. Its ultimate return will depend\non the clinical evidence we generate, the partnerships we secure, and the\ndiscipline with which we manage future spending.\n\nCD228V and the Opportunity in Targeted Cancer Therapy\n\nAntibody-drug conjugates, or ADCs, combine an antibody that recognizes a\ntarget on cancer cells with a potent cancer-killing payload. Their promise\nlies in directing treatment toward tumor cells, although the balance between\nantitumor activity and toxicity depends on the target, molecular design, and\nclinical setting.\n\nCD228V brings together a less crowded solid-tumor target, second-generation\nmolecular engineering, and an existing clinical and manufacturing foundation.\nIt targets melanotransferrin, also known as CD228, a cell-surface protein\nassociated with melanoma and expressed across several other solid tumors. Its\nexpression and potential for internalization make it an attractive target for\ndelivering an ADC payload.\n\nOur initial priority is melanoma, particularly relapsed, refractory, or\nimmunotherapy-resistant disease, where additional treatment options are\nneeded. We intend to integrate biomarker work into development to better\nunderstand which patients may benefit.\n\nWe believe CD228V also has potential beyond melanoma, including in\nCD228-expressing lung, head and neck, and esophageal cancers. CD228V is early\nin development, and neither its efficacy nor an improved safety profile has\nbeen established; no approved therapy has yet validated CD228 as a treatment\ntarget.\n\nWe believe the combination of target biology, molecular design, and\ndevelopment readiness gives CD228V a compelling place in our portfolio. Our\ngoal is to translate that foundation into evidence that can support further\ndevelopment and attract partners with complementary capabilities.\n\nSkinJect and a Focused Gorlin Syndrome Strategy\n\nWe completed the SKNJCT-003 Phase 2 study, evaluated its findings, and\nidentified the 200-microgram dose for further development. The FDA\nsubsequently authorized initiation of SKNJCT-005, our planned registrational\nstudy in patients with Gorlin syndrome, an autosomal dominant rare disease.\n\nPatients with Gorlin syndrome face a lifetime burden of recurrent basal cell\ncarcinomas and repeated procedures. We believe this population provides a\nfocused setting in which to evaluate SkinJect as a localized treatment option.\n\nThe completed work has informed dose selection and defined the next study,\nproviding a clearer basis for allocating resources and evaluating potential\npartnerships. Additional clinical evidence and regulatory review remain\nnecessary.\n\nTeverelix and Partner Ready Development Opportunities\n\nThe acquisition of Antev in August 2025 expanded our portfolio into urology\nand women’s health through Teverelix, an investigational, next generation,\nGnRH antagonist. We subsequently strengthened its underlying economics by\nreducing the royalty rate and refined its priorities to acute urinary\nretention relapse prevention and symptomatic endometriosis, alongside a\npartnership-led strategy in advanced prostate cancer patients with high\ncardiovascular risk profile.\n\nOur recent submission of an optimized registrational protocol for advanced\nprostate cancer is intended to incorporate previously FDA-cleared\ndose-optimization work into a proposed integrated development program. Subject\nto FDA review, this approach is designed to give potential partners a clearer\nplan for advancing the asset.\n\nThe Next Phase of Execution\n\nOur priorities are to advance selected clinical and regulatory milestones,\nalign organizational costs with those priorities, and pursue licensing,\nco-development, and other strategic opportunities. Partnerships could\ncontribute non-dilutive development funding and expertise while reducing the\ncapital Medicus would otherwise need to provide. Their timing, terms, and\ncompletion remain uncertain.\n\nFor our shareholders, we continue to strive to help make the connection\nbetween our portfolio and potential value more tangible. We are committed to\nexplain the significance of each milestone, the resources required to reach\nit, and the decisions it enables. The measure of our progress should be\nstronger clinical evidence, clearer development pathways, and transactions\nthat support continued advancement.\n\nWe remain confident in the purpose of our work and committed to responsible\ncapital allocation. We have built a company with a broader scientific\nopportunity than when we began. Our mission is to demonstrate what that\nopportunity can deliver for patients and shareholders.\n\nFor further information contact:\n\nCarolyn Bonner, President and Chief Financial Officer\n(610) 636-0184\ncbonner@medicuspharma.com\n\nAnna Baran-Djokovic, SVP Investor Relations \n(305) 615-9162\nadjokovic@medicuspharma.com\n\nAbout Medicus Pharma Ltd.\n\nMedicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences\ncompany focused on advancing the clinical development programs of novel and\npotentially disruptive therapeutic assets. The Company is actively engaged in\nmultiple countries across three continents.\n\nThe Company’s current therapeutic assets are:\n\nCD228V ADC, an investigational antibody-drug conjugate molecule utilizing\nPfizer’s established vedotin linker-payload platform, directed against\nmelanotransferrin (CD228), a cell-surface protein expressed across multiple\nsolid tumor types, such as melanoma, squamous non-small cell lung cancer\n(NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.\n\nSkinJect®, an investigational novel localized immuno-oncology precision\nproduct focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome\npatients, a rare autosomal dominant disease also called nevoid BCC syndrome.\n\nTeverelix®, an investigational next-generation GnRH antagonist, is being\ndeveloped as a first-in-market product for cardiovascular high-risk advanced\nprostate cancer patients, patients with acute urinary retention relapse (AURr)\nepisodes due to enlarged prostate and symptomatic endometriosis.\n\nMedicus’ strategy is to advance select programs through Phase 2\nproof-of-concept and key clinical and regulatory inflection points that\nsubstantially reduce development risk and increase their attractiveness to\npotential pharmaceutical partners. By generating decision-grade clinical,\nregulatory and operational datasets, the Company seeks to create opportunities\nfor strategic collaborations, regional licensing transactions and broader\ncommercialization partnerships with established pharmaceutical companies. As\ndata matures across its programs, Medicus intends to continue building\ndifferentiated development packages designed to maximize asset value while\nmaintaining capital efficiency and development focus.\n\nCautionary Notice on Forward-Looking Statements\n\nCertain information in this news release constitutes “forward-looking\nstatements” or “forward-looking information” within the meaning of the\nU.S. Private Securities Litigation Reform Act of 1995 and other applicable\nsecurities laws (collectively, “forward-looking statements”).\n“Forward-looking statements” are defined as disclosure regarding possible\nevents, conditions or financial performance that is based on assumptions about\nfuture economic conditions and courses of action and includes, without\nlimitation, statements regarding the development of SkinJect® and the\npotential benefits thereof for those suffering with Gorlin Syndrome, the\nplanned initiation, timing, design, conduct and results of the SKNJCT-005\nregistrational study in patients with Gorlin Syndrome, the development of\nTeverelix® and expectations concerning, and future outcomes relating to, the\ndevelopment, advancement and commercialization of Teverelix® for AURr,\ncardiovascular high-risk advanced prostate cancer, women’s health\nindications like endometriosis, the FDA’s feedback regarding the Company’s\nPhase 2b/3 registration-intent protocol for Teverelix® in APC, the proposed\ndesign of the Phase 2b/3 registration-intent program, the potential to reduce\nthe overall planned APC clinical development program from approximately 1,500\npatients to approximately 600 patients, the establishment of a defined,\ncapital-efficient and partner-ready registrational pathway for Teverelix®\nwithout Medicus independently funding an additional APC clinical development\nstudy, Medicus’ intent and ability to out-license or otherwise strategically\npartner the Teverelix® APC program, the anticipated completion of GMP-grade\nmanufacturing, quality-release and other clinical study readiness steps before\nthe end of 2026, whether the proposed cardiovascular-focused registrational\nstrategy, including the 12-month non-calcified coronary plaque endpoint\nassessed using non-invasive coronary CCTA and the evaluation of Teverelix®\neffects on APC patients at increased cardiovascular risk, could support\nregistration, the Company’s capital-efficient portfolio strategy and the\nanticipated benefits thereof, the Company’s co-development with Pfizer with\nrespect to CD228V and the anticipated benefits thereof, the Company’s plans\nand expectations relating to the development, manufacture and\ncommercialization of CD228V across human therapeutic indications, including\nthe Company’s intention to focus initial development on melanoma with\npotential subsequent development in squamous non-small cell lung cancer\n(NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer,\nthe timing, design, conduct and results of any future clinical study of\nCD228V, and the potential market opportunities related to CD228V, SkinJect®\nand Teverelix® and the Company’s other therapeutic assets. Forward-looking\nstatements are often, but not always, identified by the use of such terms as\n\"may\", “on track”, “aim”, \"might\", \"will\", \"will likely result\",\n“could,” “designed,” \"would\", \"should\", \"estimate\", \"plan\", \"project\",\n\"forecast\", \"intend\", \"expect\", \"anticipate\", \"believe\", \"seek\", \"continue\",\n\"target\", “goal”, “strive”, “intended”, “potential” or the\nnegative and/or inverse of such terms or other similar expressions. These\nstatements involve known and unknown risks, uncertainties and other factors,\nwhich may cause actual results, performance or achievements to differ\nmaterially from those expressed or implied by such statements, including those\nrisk factors described in the Company's annual report on form 10-K for the\nyear ended December 31, 2025, and in the Company's other public filings on\nEDGAR and SEDAR+, which may impact, among other things, the trading price and\nliquidity of the Company's common shares. Forward-looking statements contained\nin this news release are expressly qualified by this cautionary statement and\nreflect our expectations as of the date hereof and thus are subject to change\nthereafter. The Company disclaims any intention or obligation to update or\nrevise any forward-looking statements, whether as a result of new information,\nfuture events or otherwise, except as required by law. Readers are further\ncautioned not to place undue reliance on forward-looking statements as there\ncan be no assurance that the plans, intentions or expectations upon which they\nare placed will occur. Such information, although considered reasonable by\nmanagement at the time of preparation, may prove to be incorrect and actual\nresults may differ materially from those anticipated.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0f5af1d1-dfba-4810-baac-d1922c0558c1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T12:00:01.20958089Z","server_sent_at_ms":1791460801209},"received_at":"2026-10-08T12:00:01.261Z","source_url":null},"analysis":{"id":"152616","press_release_id":"164185","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["management acknowledges stock-price volatility and pullback","CD228V is early-stage with no established efficacy or validated target","partnership timing, terms, and completion remain uncertain"],"eventType":"operations_update","narrative":"Medicus Pharma issued a third-anniversary shareholder update recapping its transformation into a precision oncology-led biotech with three assets: CD228V ADC, SkinJect, and Teverelix.\n\nKey program status: the FDA authorized the SKNJCT-005 registrational study for SkinJect in Gorlin syndrome, and the company submitted an optimized Teverelix registrational protocol for advanced prostate cancer that could shrink the program from roughly 1,500 to 600 patients.\n\nThe company disclosed approximately $90 million raised to date via equity and debt, acknowledged stock-price volatility, and flagged partnership-driven, non-dilutive funding as a strategic priority with uncertain timing and terms.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Milestone-recap letter with no new data; watch for SKNJCT-005 initiation and FDA feedback on the Teverelix protocol as real catalysts."},"keyFigures":{"customDimensions":{"capital_raised_to_date":"$90 million","planned_apc_program_size_reduction":"approximately 1,500 patients to approximately 600 patients"}},"namedEntities":{"people":[{"name":"Carolyn Bonner","role":"President and Chief Financial Officer"},{"name":"Anna Baran-Djokovic","role":"SVP Investor Relations"}],"products":["CD228V","SkinJect","Teverelix"],"companies":[{"name":"Medicus Pharma Ltd.","ticker":"MDCX","relationship":"filer"},{"name":"Pfizer","relationship":"platform licensor / co-development partner"},{"name":"Antev","relationship":"acquired company"}],"dollarAmounts":[{"amount":"$90 million","context":"cumulative equity and debt financing raised over three years"}]},"materialImpact":{"score":2,"reasoning":"Anniversary shareholder letter recapping known pipeline progress (SkinJect registrational study authorized, Teverelix protocol submitted, CD228V early-stage) with no new clinical data, figures, or regulatory decisions."},"tickerRelevance":{"others":[],"primary":"MDCX"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap biotech","eventGravity":"anniversary shareholder update, no new data","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"neutral","material_impact_score":2,"narrative":"Medicus Pharma issued a third-anniversary shareholder update recapping its transformation into a precision oncology-led biotech with three assets: CD228V ADC, SkinJect, and Teverelix.\n\nKey program status: the FDA authorized the SKNJCT-005 registrational study for SkinJect in Gorlin syndrome, and the company submitted an optimized Teverelix registrational protocol for advanced prostate cancer that could shrink the program from roughly 1,500 to 600 patients.\n\nThe company disclosed approximately $90 million raised to date via equity and debt, acknowledged stock-price volatility, and flagged partnership-driven, non-dilutive funding as a strategic priority with uncertain timing and terms.","key_figures":{"customDimensions":{"capital_raised_to_date":"$90 million","planned_apc_program_size_reduction":"approximately 1,500 patients to approximately 600 patients"}},"named_entities":{"people":[{"name":"Carolyn Bonner","role":"President and Chief Financial Officer"},{"name":"Anna Baran-Djokovic","role":"SVP Investor Relations"}],"products":["CD228V","SkinJect","Teverelix"],"companies":[{"name":"Medicus Pharma Ltd.","ticker":"MDCX","relationship":"filer"},{"name":"Pfizer","relationship":"platform licensor / co-development partner"},{"name":"Antev","relationship":"acquired company"}],"dollarAmounts":[{"amount":"$90 million","context":"cumulative equity and debt financing raised over three years"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T12:00:19.761Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap biotech","eventGravity":"anniversary shareholder update, no new data","issuerAuthored":true}},"durationMs":5959,"modelName":"glm-5.3-flashx"}}